IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

# A SYSTEMATIC REVIEW OF EBOLA VIRAL DISEASE.

**Dr.Aamer Quazi Sir ,Vijay.L.Gade, Sujit.N.Shelake , Akash.M.Gaikwad ,**

Professor*,Student[1], Student [2], Student [3]

ASPM'S K.T.PATIL COLLEGE OF PHARMACY, OSMANABAD M.S-413501 India.

**ABSTRACT:**

Ebola virus is transmitted to people as a result of direct contact with body fluids containing virus of an infected case. The incubation period generally lasts 5 to 7 d and roughly 95 of the cases appear signs within 21 d after exposure. Typical features include fever, profound weakness, diarrhea, abdominal pain, cramping, nausea and puking for 3- 5 days and perhaps persisting for over to a week. Laboratory complications including elevated aminotransferase situations, pronounced lymphocytopenia, and thrombocytopenia may have passed. Hemorrhagic fever occurs in lower than half of cases and it takes place most generally in the gastrointestinaltract.Ebola contagion complaint( EVD) is a life- hanging viral complaint with a casualty rate ranging from around 30 to 90. The first EVD outbreak was reported in the 1970s in Zaire( now the Democratic Republic of the Congo). Until 2013, utmost outbreaks passed in the Central Africa region, including Zaire, Sudan and Uganda. still, between March and October 2014, over 10000 cases of EVD have been recorded in West Africa, similar as in Guinea, Liberia, Sierra Leone, and Nigeria, and a many sanitarium or secondary infections of EVD have passed in Spain and the United States of America. EVD is presently one of the world's most stressed conditions. In this literature review, we describe the epidemiology, clinical features, opinion, and treatment of EVD.

## Objective:

Ebola virus disease (EVD) is a life-threatening viral disease. Death rate ranges between 30% and 90%, the first EVD outbreak was reported in the 1970s in Zaire. The global danger of this virus requires the need for producing effective vaccines and drugs is facing its outbreak threat. Even though there is no available commercial vaccine so far against EBOV, a few vaccine candidates are under evaluation to examine their therapeutic efficacy.

**Keywords**: Ebola virus, Outbreak, Treatment, Hemorrhagic fever.

- **Introduction**

Ebola virus (EBOV) belongs to the family Filoviridae, the genus Ebolavirus, and frequently causes fatal infection in humans. EBOV disease (EVD) may show multiple, serial, and nonspecific-disease symptoms including high fever, headache, vomiting, anorexia, diarrhea, and aching muscles. Unexplained bleeding in the eyes, nose, gums, and gut occurs in the advanced stages. The first outbreak of EVD was reported in 1976 in the Democratic Republic of the Congo[5]. Since then, there have been reports of small EVD outbreaks in somecountries in Central Africa, including Sudan and Uganda with an estimated 2350 cases of EVD occurring between the1970s and 2013. The disease can therefore be regarded as endemic to some areas of Central Africa. In March 2014, an outbreak of EVD was reported for the first time in West Africa, in Guinea, and it spread rapidly to neighboring countries including Liberia and Sierra Leone, creating a serious epidemic.This has caused major health concerns both in and beyond the region, with the World Health Organization (WHO) and numerous countries initiating health monitoring and containment measures. We describe here the previous and current epidemics, epidemiology, clinical features, diagnosis, and treatment of EVD as described to date in the literature.

EVD epidemics from the 1970s to 2013 Summarized epidemics data from the 1970s to 2013 are shown in EVD first emerged in 1976 in the Democratic Republic of Congo (DRC) and at around the same time in Sudan. Among these epidemic areas, 318 cases were recorded in DRC and 284 cases in Sudan. As the first reports of the epidemic occurred near the Ebola River, DRC, the disease became known as Ebola hemorrhagic fever (EHF), and two different species of EBOV were confirmed: EBOV-Zaire (EBOV-Z) and EBOV-Sudan (EBOV-S). In 1977, one fatal case due to EBOV-Z was reported in Zaire, and EBOV-S subsequently reemerged with 34 cases, 22 of which were fatal, in Sudan in 1979. No further cases were recorded until 1994, when a new species of EBOV was confirmed in a non-fatal case in the Ivory Coast and named EBOV-IC. One case was confirmed who had traveled from Liberia to Sierra Leone and had antibodies to EBOV, suggesting existence of EBOV-IC in Liberia. These episodes suggest that EBOV had spread from areas in Central Africa to West Africa. In 1995, EVD due to EBOV-Z reemerged in the DRC. An estimated 315 cases and 250 deaths (CFR: 81%) occurred during this large epidemic. The EBOV-Z species identified was shown to have a close genetic relationship with the strains isolated in 1976 in Zaire. EBOV-S then emerged in Uganda during 2000-2001, resulting in an estimated 425 cases and 224 deaths (CFR: 53%). The EBOV species identified could be clearly placed among the EBOV-S strains isolated in 1976 in Sudan[In 2004, an EBOV-S outbreak of 17 cases and 7 deaths (CFR: 41%) was reported in Yambio County, South Sudan. The index case had butchered a monkey, and human-to-human transmission was mainly through direct contact. Outbreak of EBOV-Z occurred in the Republic of Congo in 2002-2003 with 143 cases (128 deaths, CFR: 89%) and in the DRC in 2007, with 264 suspected cases and 187 deaths (CFR: 71%) recorded [In November 2007, a new EBOV species, designated Bundibugyo ebolavirus (EBOV-B), was identified in Western Uganda, and 149 suspected cases and 37 deaths had been reported by January 2008 as the outbreak neared conclusion. In the 2008 Ebola outbreak, there were 32 cases including 15 deaths (CFR: 47%) in Kasai Occidental Province in the DRC. In May 2011, a patient with suspected EHF died after contacting EBOV-S in Luwero District, Uganda, and the following year an outbreak among 11 patients resulted in 4 deaths from EHF in Kibaale District. Another EVD outbreak occurred in the DRC.




**Figure 1.** Detailed geometric data of the EVD outbreak.
The data shown are based on a report by the WHO[28].

- **Structure of E. virus E. virus :**

A filamentous shape virus with confines of 800 nm long and 80 nm in periphery and has an encapsulated single- stranded negative RNA. There are seven expressed proteins by Ebola Nucleoprotein( NP), glycoprotein( GP), RNA-dependent RNA polymerase( L), and four structural viral proteins( VP24),( VP30),( VP35), and( VP40).

- The part of these proteins is epitomized as follows.
- NP Essential for RNA encapsulation.
- GP Essential for the attachment of the virus to the host cell membrane and entering the nucleocapsid of the virus into the host cytoplasm.
- VP24 Essential for virus assembling and in recap by being part of the nucleocapsid structure o VP30 repression of viral RNA silencing .
- VP35 Binds to NP to remove the nucleocapsid to grease the transcriptional expression.

- VP40 needed for virus localization out of the host cell membrane and gives filamentous shape to contagion together with GP and helps maintain the structural integrity.

- **LIFE CYCLE :**

The natural force host of E. contagion is fruit bludgeons and accidental hosts are humans and non-mortalprimates.E. contagion can be directly transferred by blood or body fluids analogous as urine, saliva, sweat, feces, bone milk, andsemen.E. virus also can be transferred by sexual contact. After entering the body through small injuries on the skin or mucous membranes, the contagion targets monocyte/ macrophages and dendritic cells. The infection also spreads through the lymphatic vessels to indigenous lymph bumps and from there causes secondary viremia infecting the spleen, liver, and adrenal glands. Way of the contagion life cycle Contagions attach to the host receptors by GP which is endocytosed into vesicles in the host cell. also, the viral membrane fuses with the vesicle membrane, and the nucleocapsid is released into the cytoplasm. The recap of RNA process begins with the list of the polymerase complex to a single list point located within the leader region of the genome. The complex also slides along the RNA template and successively transcribes the individual genes in their 3 ' – 5 ' order. Encapsidated, negative- sense genomic ssRNA is used as a template for the emulsion( 3 ' – 5 ') of polyadenylated, monocistronic mRNAs and, using the host cell's ribosomes, tRNA molecules,etc., the mRNA is paraphrased into individual viral proteins, with an increase of viral protein situations, a switch occurs from paraphrase to replication. Assembly starts by the nucleocapsids which accumulate in the perinuclear transported to the budding spots at the tube membrane. Expiring occurs at the tube membrane where VP40 and GP play important places in the budding process. ultimately, the virion is released Region.

- **Modes of transmission :**

Fruit batons of the Pteropodidae family are the natural hosts of the Ebola virus. Pandemics of EVD are introduced into the mortal population through close contact with infected creatures, similar as batons, chimpanzees, monkeys, and antelope, which is called a spillover event. Secondary mortal- to- mortal transmission occurs when mucous membranes come into direct contact with the blood, concealment, or other body fluids of the infected individualities. The most contagious body fluids are vomitus, feces, and blood. contagious virus is also set up in slaver, urine, semen, and bone milk. Although the cases recovered from EVD, the contagion may still be present in some body fluids indeed it's no longer detected in the blood. This occurs known as the convalescent period. For case, the virus can be transmitted through semen for over to seven weeks after recovery.

- **Pathophysiology** :

Upon entry of the Ebola virus into the cases, studies have proven that the contagion can infect multiple cell types. Ebola virus enters the mucous membranes of the cases, enters the skin, or infect the vulnerable cell parenterally similar as monocytes, macrophages, and dendritic cells (DCs). Research studies have shown that the original target of the Ebola virus is the antigen- presenting cells including DC and macrophages where both cells are productively infected by the Ebola virus in vitro. Ebola viruses belong to the family Filoviridae which can divide fleetly within the vulnerable cells that affect in necrosis and release the infected cells into the extracellular fluid. This virus induces repression of typeI interferon responses by the systemic spreading of the virus. Spreading of the virus into the lymph bumps can beget farther migration into the DCs and macrophages that are present in the liver, spleen, thymus, and lymphoid apkins through the bloodstream. also, other cells can also be infected similar as endothelial cells, fibroblasts, hepatocytes, fibroblast, adrenal cortical cells, and epithelial cells. These infected cells beget the appearance of the sign and symptoms of the complaint where cases suffer from loss of impunity to fight against the infection due to necrosis of lymphocytes and reduced clotting factor due to infected hepatocytes. Likewise, gastrointestinal dysfunction in EVD cases is caused by the circulating virus present in the gastrointestinal tract and seditious cytokines. The infected macrophage also releasespro-inflammatory intercessors due to systemic seditious response to the virus. The medium of coagulation abnormalities isn't directly associated with the seditious response. Again, it's a due expression of towel factor by macrophage that triggers the overactivation of the foreign pathway of coagulation. This results in impairment of the blood clotting known as coagulopathy. DCs have an important part in adaptive impunity where infection of these cells can beget apoptosis and vitiate the capability of DCs to suffer development. Infected DCs will fail to present the antigens to naïve lymphocytes and are unfit to produce antibodies against the virus. Hence, this shows how fatal the complaint can be and how filovirus can beget similar damage to the cell apkins. The medium of the Ebola contagion complaint progression is presented in.

- **Symptoms of the disease:**

The incubation period generally extends 5 – 7 days, although it can be as minimal as 2 days and as outside as 21 days. roughly 95 of the cases show signs within 21 days after the infection which is the recommended period for the follow- up of the complaint. Typical symptoms include fever, profound weakness, diarrhea, abdominal pain, cramping, nausea, and puking for 3 – 5 days and may persist for over to a week. Laboratory complications including elevated aminotransferase situations pronounced lymphocytopenia, and thrombocytopenia may do. Clinical EHF

is featured by unforeseen onset of fever, fatigue, chills, general malaise, headaches, myalgia, anorexia, and gastrointestinal torture within 3 – 13 days following exposure to the virus.




**Fig. 1: Structure of *Ebola virus* [18]**

- **DIAGNOSIS:**

Rapid and dependable opinion of EVD is essential for applicable and effective case operation. Opinion of suspected cases is verified by EBOV-specific laboratory tests that descry the EBOV genome (e.g., rear transcriptase polymerase chain response (RT- PCR). During the period of Ebola infection, viral RNA can be detected by RT- PCR in slaver, gashes, sweat, bone milk, urine, vaginal fluid, and seminal fluid anyhow of the acute complaint. Infection can also be diagnosed by dimension of the EBOV antigen or specific antibodies, IgM antibodies can be detected starting from 2 days after the first symptoms appear and vanish after 30 – 168 days. IgG response is generally considered to start between 6 and 18 days post-onset of illness and remains sensible for times. In the once 10 months, the West Africa EVD outbreak has stimulated the development of new individual tests, including rapid-fire antigen discovery tests and nucleic acid discovery tests similar as circle- intermediated isothermal modification assays

- **INFECTION CONTROL AND TREATMENT :**

Immediate insulation of infected cases is veritably important before pacing in any action.The threat of E. contagion infection can be dropped by preventing contact with blood or body fluids from infected people, addition to avoid visiting the cases in the sanitarium, and by careful hand washing and hygiene. It's necessary to hesitate from suckling for the possibility of transmission of the contagion through the milk, in addition to safe coitus practices, especially after the appearance of infection after the recovery of infected people. So far, there's no sanctioned safe and effective treatment for EVD. Current treatment is simply probative, including the control of pain and secondary infections, as well as fluid remedy. Symptoms and complications of EVD should be treated incontinently after they do. Hypovolemia due to massive fluid loss through puking and diarrhea is the most common symptom of EVD. therefore, it's necessary to maintain fluid volume by modulation. The electrolyte rates regulate the diurnal fluid input and affair. It was also observed that antiemetic and antidiarrheal medicines may limit the massive loss of fluids and should be approved when circulated intravascular coagulation develops. They must control the coagulation factors, the remedy of thrombocytopenia and anemia. In addition, respiratory failure is more frequently secondary to EVD complications, and thus, oxygen remedy in severe cases should be use.




**Fig. 2: *Ebola virus* transmission. Source: Centre for Disease Control [24]**

Table 2: Table of drug clinical trials

| Product/company | Phase | Trial location | Description |
|---|---|---|---|
| Favipiravir Fujifilm/Toyama, Japan | Phase II | By INSERM in Guinea: Conakry, Guéckedou, Macenta, Nzérékoré | Used to treat influenza<br>The drug has been administered to around 200 patients who received 9 days of oral treatment. There is no control group<br>The EU has announced preliminary findings from these trials which show the antiviral may be effective in treating patients with early-stage EVD. In adults and adolescents with a low to moderate viral load, the case fatality rate was 15% (vs. 30%, historically). WHO is taking a cautious interpretation given the lack of concurrent controls in the study |
| TKM-100802 (siRNA) Tekmira, Canada | Phase II | By Oxford University in Kerry Town, Sierra Leone | siRNA – a short RNA sequence that cleaves Ebola RNA in cells and prevents virus multiplication. Treats 100% of infected monkeys<br>A clinical trial started in early March 2015 in Port Loko, Sierra Leone, led by Oxford University with funding from the Wellcome Trust<br>The trial was halted on June 19 on the grounds of having met one of the clinical endpoints. Continuing enrolment was not likely to demonstrate an overall therapeutic benefit |
| ZMapp Mapp USA | Phase II | By NIAID in Liberia, Sierra Leone and the United States of America | The product has been used on several patients under compassionate use<br>A multi-country, the multisite randomized controlled trial opened to enrollment in Liberia and the United States in February 2015 and in Sierra Leone in March 2015. Enrollment is ongoing – currently, more than 35 patients have been enrolled<br>No data on efficacy are available yet<br>Preparations to extend this trial to Guinea (in collaboration with INSERM) are in progress |
| MIL-77 MathWorks, China | Phase I | | Efficacy in monkeys comparable to Zmapp<br>To date, used in two expatriated patients under compassionate use<br>IND for Phase I filed in China<br>Prioritized for use on Ebola patients in the condition of not interfering with the clinical assessment of the efficacy of Zmapp |
| BCX-4430 Biocryst, USA | Phase I | By Quotient Clinic in the UK | Broad-spectrum direct-acting nucleoside analog<br>Phase I safety trial is underway. No efficacy trial is planned until safety data have been analyzed |
| Interferons | Phase II | By Guinea MOH in Coyah, Guinea | Approved for the treatment of Hep B and C and multiple sclerosis |
| Amiodarone | Observational | At the Lakka and Goderich ETU in Sierra Leone | Used to treat cardiac dysrhythmia<br>Was used compassionately in approximately 80 patients in Sierra Leone and reportedly reduced case fatality ratio when compared with local historical norms. The statistical significance of this result is not known due to variations in case fatality rates across sites and overtime<br>This treatment is no longer being used |
| Atorvostatin+Irbesartan ±Clomiphene | | Sierra Leone | Approved for cholesterol control/hypertension/infertility, respectively<br>Apparently used to treat some patients in Sierra Leone; however, there has been no confirmation from the treatment centers that such studies took place, and no clinical data on the patients are available. Therefore, no conclusion on utility, safety or efficacy is possible |
| Amodiaquine | | Médecins Sans Frontiéres (MSF) | Antimalarial products were provided to all patients entering Ebola treatment centers. When MSF switched from an antimalarial containing lumefantrine to one containing amodiaquine, the case fatality rates dropped<br>It is not known if this is due to the efficacy of amodiaquine against Ebola or the toxicity of lumefantrine in patients with EVD |
| Brincidofovir Chimerix, USA | Phase II | By Oxford University at the ELWA 3 Clinic, Monrovia, Liberia | An antiviral used to treat CMV<br>Clinical trial halted and abandoned; the drug has been deprioritized for use in Ebola treatment |

Source: World Health Organization [40]

WHO has issued a document for the bracket, testing, and use of medicines in cases who are infected with the E. virus. With the global effect of the West Africa outbreak EVD, exploration and development for new Ebola vaccine campaigners have been stimulated, though no authorized vaccine is presently available. preliminarily, the development of vaccine campaigners has led to the inauguration of Phase I, II, and III mortal clinical trials. The current EVD outbreak urges the health care and public health systems to respond to contagious complaint extremities and develop the healthcare structure in developing countries and to increase mindfulness in countries at threat for EVD imported cases. Mortal Ebola outbreaks generally do suddenly with a posterior rapid-fire spread from person to person.E. viruses are largely contagious contagious. Understanding the clinical aspects,

immediate opinion and suitable treatment are major way toward the forestallment of death and transmission of the virus to other people.

- **Conclusion:**

EVD is a malign complaint that causes several outbreaks primarily in Africa. The exact source of where the Ebola virus came from is still unknown till moment, but it's believed that the Ebola contagion is beast- borne as the creatures which are infected with the virus will beget the direct transmission to other creatures. The rearmost outbreak in November 2020 recorded 130 EVD cases including 119 verified and 11 probable cases from 13 health zones, which claimed 55 lives. As of now, veritably limited medicines and treatment options are available for EVD. EVD is a painful memorial that an outbreak anywhere can be a threat far and wide. The Global Health Security Agenda seeks to apply public health systems in most affected countries in order to exclude the spreads before they come extremities. Although great advancements have been achieved over the once decade, better surveillance, real- time sharing of data and taking rapid-fire action grounded on the available information remain necessary. Because Ebola virus is primarily transmitted through contact with the body fluids of characteristic cases, the infection spread can be stopped by an early opinion, contact dogging, patient insulation and care, infection control and safe burial.

## References

[1] World Health Organization. Ebola virus disease. WHO. Available on: ⟨https:// www.who.int/news-room/fact-sheets/detail/ebola-virus-disease⟩ (accessed on 28 December 2020).

[2] Centers for Disease Control and Prevention. 2014–2016 Ebola Outbreak in West Africa. Available on: ⟨https://www.cdc.gov/vhf/ebola/about.html⟩ (accessed on 28 December 2020).

[3] Leroy EM, Rouquet P, Formenty P, Souquière S, Kilbourne A, Froment JM, et al. Multiple Ebola virus transmission events and rapid decline of central African wildlife. Science 2004;303(5656):387–90. https://doi.org/10.1126/science. 1092528. Erratum in: Science. 2004 Jan 20;303(5658):628. PMID: 14726594.

[4] Ströher U, Feldmann H. Progress towards the treatment of Ebola haemorrhagic fever. Expert Opin Invest Drugs 2006;15(12):1523–35. https://doi.org/10.1517/ 13543784.15.12.1523

[5] Goldstein T, Anthony SJ, Gbakima A, Bird BH, Bangura J, Tremeau-Bravard A, et al. The discovery of Bombali virus adds further support for bats as hosts of ebolaviruses. Nat Microbiol 2018;3(10):1084–9. https://doi.org/10.1038/s41564-018- 0227-2. Epub 2018 Aug 27. Erratum in: Nat Microbiol. 2018 Dec;3(12):1486. PMID: 30150734; PMCID: PMC6557442.

[6] Centers for Disease Control and Prevention. History of Ebola outbreaks. Available on: ⟨https://www.cdc.gov/vhf/ebola/history/2014–:~:text=The%20impact%20⟩ (accessed on 28 December 2020).

[[7] Bannister B, Puro V, Fusco FM, Heptonstall J, Ippolito G, EUNID Working Group. Framework for the design and operation of highlevel isolation units: consensus of the European Network of Infectious Diseases. Lancet Infect Dis 2009; 9(1): 45-56.

[8] Kugelman JR, Sanchez-Lockhart M, Andersen KG, Gire S, Park DJ, Sealfon R, et al. Evaluation of the potential impact of ebola virus genomic drift on the efficacy of sequence-based candidate therapeutics. mBio 2015; doi: 10.1128/mBio.02227-14.

[9] Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011; 377(9768): 849-62.

[10] Mehedi M, Falzarano D, Seebach J, Hu XJ, Carpenter MS, Schnittler HJ, et al. A new Ebola virus nonstructural glycoprotein expressed through RNA editing. J Virol 2011; 85(11): 5406-14.

[11] Marzi A, Yoshida R, Miyamoto H, Ishijima M, Suzuki Y, Higuchi M, et al. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS One 2012; doi: 10.1371/journal.pone.0036192.

[12] Stein RA. What is Ebola? Int J Clin Pract 2015; 69(1): 49-5813. Kumar S, Kumari R, Pandey R, Sharma V. Ebola virus disease: Biology, Fig. 3: The life cycle of Ebola, Source: ViralZone, Swiss Institute of Bioinformatics

[13]. Kumar S, Kumari R, Pandey R, Sharma V. Ebola virus disease: Biology, Fig. 3: The life cycle of Ebola, Source: ViralZone, Swiss Institute of Bioinformatics [29] diagnosis, Proc Indian Natl Sci Acad 2017;83:103-49.

[14]. Parasuraman P, Suresh RS, Perumal P. Searching antiviral drugs for Ebola virus from phytoconstituents of Azadirachta indica: Application of molecular modelling studies. Asian J Pharm Clin Res 2017;10:254-7.

[15] Madariaga MG. Ebola virus disease: A perspective for the United States. Am J Med 2015;128:682-91.

[16]. Cantoni D, Rossman JS. Ebolaviruses: New roles for old proteins. PLoS Negl Trop Dis 2018; 12:e0006349.

[17]. Munjita SM, Kwenda G. Descriptive analysis of bola virus proteins: Towards development of effective therapeuticsand vaccines. Br Microbiol Res J 2015; 8:457-79.

[18]. Avaliable from: https://www.fineartamerica.com/featured/ebola-virusillustration-evan-oto.html?product=art-print.

[19]. Centers for Disease Control and Prevention, Ebola virus Disease EVD; 2018. Available from: http://www.cdc.gov/vhf/ebola.

[20]. Ruparelia C, Curless M, Trexler P, Black M. Prevention and Control of Ebola Virus Disease in Health Care Facilities with Limited Resources, Reference Manual; 2015.

[21]. Fischer WA, Brown J, Wohl DA, Loftis AJ, Tozay S, Reeves E, et al. Ebola virus ribonucleic acid detection in semen more than two years after resolution of acute Ebola virus infection. Open Forum Infect Dis 2017; 4:ofx155.

[22]. Boon SD, Marston BJ, Nyenswah TG, Jambai A, Barry M, Keita S, et al. Ebola virus infection associated with transmission from survivors. Emerg Infect Dis J 2019; 25:2019.
[23]. Mustafa M, Yusof MI, Kassim M, Jeffree MS, Illzam EM, Sharifa AM. Ebola virus disease, management, and prevention. IOSR J Dent Med Sci 2016; 15:142-8.
[24]. Available from: https://www.cdc.gov/vhf/ebola/resources/virus-ecology. Html.
[25]. Yu DS, Weng TH, Wu XX, Wang FXC, Lu XY, Wu HB, et al. The lifecycle of the Ebola virus in host cells. Oncotarget 2017; 8:55750-9.
[26]. Madelain V, Nguyen TH, Olivo A, de Lamballerie X, Guedj J, TaburetAM, et al. Ebola virus infection: Review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials. Clin Pharmacokinet 2016; 55:907-23.
[27]. Salata C, Calistri A, Alvisi G, Celestino M, Parolin C, Palù G, et al. Ebola virus entry: From molecular characterization to drug discovery. Viruses 2019; 11:E274. Al-Tameemi and Kabakli Asian J Pharm Clin Res, Vol 12, Issue 10, 2019, 57-62 62
[28]. Available from: https://www.viralzone.expasy.org/5016.
[29]. Kaushal S, Kumari S. A review on Ebola virus, the diseases, causes and management. Int Res J Pharm 2017;8:1-8.
[30]. Khalafallah MT, Aboshady OA, Moawed SA, Ramadan MS. Ebola virus disease: Essential clinical knowledge. Avicenna J Med 2017; 7:96-102.
[31]. Moghadam SR, Omidi N, Bayrami S, Moghadam SJ, Seyedalinaghi S. Ebola viral disease: Review literature. Asian Pac J Trop Biomed 2015; 5:260-7.
[32]. Broadhurst MJ, Brooks TJ, Pollock NR. Diagnosis of Ebola virus disease: Past, present, and future. Clin Microbiol Rev 2016; 29:773-93.
[33]. Martínez MJ, Salim AM, Hurtado JC, Kilgore PE. Ebola virus infection: Overview and update on prevention and treatment. Infect Dis Ther 2015; 4:365-90.
[34]. Chertow DS, Kleine C, Edwards JK, Scaini R, Giuliani R, Sprecher A, et al. Ebola virus disease in West Africa clinical manifestations and management. N Engl J Med 2014;371:2054-7.
[35]. West TE, von Saint André-von Arnim A. Clinical presentation and management of severe Ebola virus disease. Ann Am Thorac Soc 2014;11:1341-50.